

---

**16:45 – 17:30 Tuesday June 22<sup>nd</sup> and Wednesday June 23<sup>rd</sup>**

**Poster session – All posters will be displayed throughout the meeting**

---

Left aligned posters = Presenting authors present by poster Tuesday June 22<sup>nd</sup> 16:45 – 17:30

Indented posters = Presenting authors present by poster Wednesday June 23<sup>rd</sup> 16:45 – 17:30

## Posters – Biology

**POB1 Identification in vitro and in vivo of tumoral glial precursor cells in neuroblastoma** Page 147

*Sandra Acosta*<sup>1</sup>; *Eva Rodriguez*<sup>1</sup>; *Cinzia Lavarino*<sup>1</sup>; *Katleen De Preter*<sup>2</sup>; *Idoia Garcia*<sup>1</sup>; *Gemma Mayol*<sup>1</sup>; *Carmen de Torres*<sup>1</sup>; *Jaume Mora*<sup>1</sup>

<sup>1</sup>Spain; <sup>2</sup>Belgium

**POB2 Integrated analysis of DNA methylation, copy number and mRNA expression** Page 147

**identifies novel candidate tumor suppressor genes in neuroblastoma**

*Leah Alcock*; *Patrick Buckley*; *Kenneth Bryan*; *Sudipto Das*; *Karen Watters*; *Raymond Stallings*  
Ireland

**POB3 Ganglioneuroblastoma, nodular subtype and MYCN amplification: the hospital for sick children experience** Page 147

*Paola Angelini*; *Paula Marrano*; *Paul Thorner*; *Meredith Irwin*; *Sylvain Baruchel*

Canada

**POB4 Interleukin-6-mediated activation of the signal transduction and activator of** Page 148

**transcription (stat)3 contributes to chemoresistance and tumor progression in neuroblastoma**

*Tasnim Ara*; *Rie Nakata*; *Nino Keshelava*; *Robert Seeger*; *Yves DeClerck*

United States

**POB5 Differential gene and pathway expression and alternate splicing in high-risk MYCN amplified and non-amplified neuroblastomas. A report from the Neuroblastoma TARGET (Therapeutically Applicable Research to Generate Effective Treatments) Initiative** Page 148

*Shahab Asgharzadeh*; *Lingyun Ji*; *Richard Sposto*; *Yue-Xian Tu*; *Michael Hadjidaniel*; *Edward Attiyeh*; *Michael D. Hogarty*; *Julie Gastier-Foster*; *Jun Wei*; *Xiang Guo*; *Daniela Gerhard*; *Malcolm A. Smith*; *Javed Khan*; *John M. Maris*; *Robert C. Seeger*

United States

**POB6 Immunogenicity of neuroblastoma - insights from experimental models** Page 148

*Shifra Ash*; *Nadir Askenasy*; *Isaac Yaniv*

Israel

**POB7 PHOX2B-mediated regulation of ALK expression in neuroblastoma pathogenesis** Page 148

*Tiziana Bachetti*; *Daniela Di Paolo*; *Valentina Mirisola*; *Chiara Brignole*; *Marta Bellotti*; *Irene Caffa*; *Chiara Ferraris*; *Michele Fiore*; *Diego Fornasari*; *Simona Di Lascio*; *Roberto Chiarle*; *Silvia Borghini*; *Ulrich Pfeffer*; *Mirco Ponzoni*; *Ceccherini Isabella*; *Patrizia Perri*

Italy

**POB8 Natural histone deacetylase inhibitor, sulforaphane, inhibits growth and survival of human neuroblastoma** Page 149

*Reza Bayat Mokhtari*<sup>1</sup>; *Herman Yeger*<sup>1</sup>; *Bikul Das*<sup>2</sup>; *Libo Zhang*<sup>1</sup>; *Sushil Kumar*<sup>1</sup>; *Gideon Koren*<sup>1</sup>;

*Sylvain Baruchel*<sup>1</sup>

<sup>1</sup>Canada; <sup>2</sup>United States

**POB9 Promoting effects of the PI3K/mTOR inhibitor PI-103 with currently applied chemotherapeutic drugs on neuroblastoma cell lines** Page 149

*Odette Besancon*; *Godelieve Tytgat*; *René Leen*; *Huib Caron*; *André van Kuilenburg*

Netherlands

**POB10 Expression of the B-cell-activating factor BAFF and its receptors in opsoclonus-myoclonus associated neuroblastoma** Page 149

*Giovanna Bianchi*<sup>1</sup>; *Verena Fühlhuber*<sup>2</sup>; *Claudio Gambini*<sup>1</sup>; *Massimo Conte*<sup>1</sup>; *Vito Pistoia*<sup>1</sup>;

*Lizzia Raffaghello*<sup>1</sup>; *Franz Blaes*<sup>1</sup>; *Barbara Hero*<sup>2</sup>

<sup>1</sup>Italy; <sup>2</sup>Germany

- POB11 Role of ATP and myeloid-derived suppressor cells in neuroblastoma microenvironment** Page 150  
*Giovanna Bianchi; Ignazia Prigione; Laura Emionite; Michele Cilli; Patrizia Pellegatti; Francesco Di Virgilio; Ilaria Marigo; Francesca Simonato; Vincenzo Bronte; Vito Pistoia; Lizzia Raffaghello*  
 Italy
- POB12 Non-transcriptional role of MYC and genomic rearrangements in neuroblastoma** Page 150  
*Anne Blumrich; Daniel Muth; Christina Poehler; Stephan Gade; Frank Westermann; Manfred Schwab*  
 Germany
- POB13 Two common fragile sites *FRA2Ctel* and *FRA2Ccen* map to the borders of *MYCN* amplicons in neuroblastoma** Page 150  
*Anne Blumrich; Marc Zapatka; Manfred Schwab; Larissa Savelyeva*  
 Germany
- POB14 Expression and clinica relevance of melanoma-associated antigens in neuroblastoma** Page 150  
*Paola Bocca<sup>1</sup>; Ignazia Prigione<sup>1</sup>; Barbara Carlini<sup>1</sup>; Maria Valeria Corrias<sup>1</sup>; Soldano Ferrone<sup>2</sup>; Vito Pistoia<sup>1</sup>; Fabio Morandi<sup>1</sup>*  
<sup>1</sup>Italy; <sup>2</sup>United States
- POB15 Heterogeneous *MYCN* amplification - amplicon, genomic background and genome instability** Page 151  
*Dominik Bogen<sup>1</sup>; Inge M. Ambros<sup>1</sup>; Gabriele Amann<sup>1</sup>; Ekkehard Spuller<sup>1</sup>; Jennie Erichsen<sup>2</sup>; Bettina Brunner<sup>1</sup>; Ruth Ladenstein<sup>1</sup>; Tommy Martinsson<sup>2</sup>; Peter F. Ambros<sup>1</sup>*  
<sup>1</sup>Austria; <sup>2</sup>Sweden
- POB16 Immunocytochemical study of bone marrow in neuroblastoma patients - Polish experience** Page 151  
*Katarzyna Bolek-Marzec; Aleksandra Wieczorek; Walentyna Balwierz*  
 Poland
- POB17 *ChIPaway*: A tool for visualization and analysis of high-throughput microarray based immunoprecipitation data** Page 151  
*Kenneth Bryan; Patrick G. Buckley; Derek M. Murphy; Sudipto Das; Raymond L. Stallings*  
 Ireland
- POB18 Genome-wide DNA methylation profiling reveals extensive and complex epigenetic alterations in neuroblastic tumors** Page 151  
*Patrick Buckley<sup>1</sup>; Sudipto Das<sup>1</sup>; Kenneth Bryan<sup>1</sup>; Raymond Stallings<sup>1</sup>; Leah Alcock<sup>1</sup>; Rogier Versteeg<sup>2</sup>*  
<sup>1</sup>Ireland; <sup>2</sup>Netherlands
- POB19 Identification of epigenetically regulated genes that predict patient outcome in neuroblastoma** Page 152  
*Helena Carén; Anna Djos; Maria Nethander; Rose-Marie Sjöberg; Per Kogner; Staffan Nilsson; Tommy Martinsson*  
 Sweden
- POB20 Factors affecting the outcome of the p53 mediated DNA damage response in neuroblastoma** Page 152  
*Jane Carr-Wilkinson<sup>1</sup>; Rebecca Griffiths<sup>2</sup>; Rebecca Elston<sup>2</sup>; Laura, D Gamble<sup>2</sup>; John Lunec<sup>2</sup>; Deborah A. Tweddle<sup>2</sup>*  
<sup>1</sup>United Kingdom; <sup>2</sup>United Kingdom
- POB21 Characterization of *ALK* rearrangements in neuroblastoma** Page 152  
*Alex Cazes; Valentina Boeva; Agnès Ribeiro; Emmanuel Barillot; Olivier Delattre; Isabelle Janoueix-Lerosey*  
 France
- POB22 Clusterin interacts with HSP60: implications in neuroblastoma development** Page 152  
*Korn-Anong Chaiwatanasirikul; Arturo Sala*  
 United Kingdom

- POB23 Human mesenchymal stromal cells (hMSCs) enhanced migration and invasion of neuroblastoma cells via SDF-1/CXCR4 and SDF-1/CXCR7 axes** Page 153  
*Godfrey Chi-Fung Chan; Ming Ma*  
Hong Kong
- POB24 Alterations of NDP kinase A/ NM23-H1 deregulate c-myc transcription** Page 153  
*Christina Chang; Kai-Hui Chan; Larry Paris; Lin-Jen Ma; Renn-Shiuan Wei; Choon-Yee Tan*  
Taiwan
- POB25 Overexpression of  $\beta$ 1,4-N-acetylgalactosaminyltransferase III suppresses the malignant phenotype of neuroblastoma cells via  $\beta$ 1-integrin signaling** Page 153  
*Mei-leng Che; Hsiu-Hao Chang; Min-Chuan Huang*  
Taiwan
- POB26 The role of protein tyrosine-phosphatases in neuroblastoma** Page 153  
*Owen Clark; Andrew Stoker*  
United Kingdom
- POB27 Identification of hypoxia signatures in neuroblastoma cell lines by I1-I2 regularization and data filtering** Page 154  
*Andrea Cornero; Paolo Fardin; Massimo Acquaviva; Annalisa Barla; Sofia Mosci; Lorenzo Rosasco; Alessandro Verri; Luigi Varesio*  
Italy
- POB28 Autophagy and its regulation in neuroblastoma** Page 154  
*Sonia Cournoyer<sup>1</sup>; Tina V Imbriglio<sup>1</sup>; Carine Nyalendo<sup>1</sup>; Claire Barelli<sup>1</sup>; Pierre Teira<sup>1</sup>; Michel Duval<sup>1</sup>; Gilles Vassal<sup>2</sup>; Hervé Sartelet<sup>1</sup>*  
<sup>1</sup>Canada; <sup>2</sup>France
- POB29 All-trans retinoic acid induced differentiation of SK-N-BE cells results in extensive DNA methylation alterations of gene promoter regions** Page 154  
*Sudipto Das; Patrick Buckley; Kenneth Bryan; Karen Watters; Niamh Foley; Leah Alcock; Isabella Bray; Raymond Stallings*  
Ireland
- POB30 Chemokines CXCR5-CXCL13 cross-talk between malignant neuroblastoma cells and schwannian stromal cells suggests a role in the inhibition of metastatic dissemination** Page 155  
*Federica Del Grosso; Simona Coco; Paola Scaruffi; Sara Stigliani; Francesca Valdora; Roberto Benelli; Simona Boccardo; Sandra Salvi; Mauro Truini; Michela Croce; Silvano Ferrini; Gian Paolo Tonini*  
Italy
- POB31 N-glycosylation of ALK as a potential target for disruption of prosurvival signaling pathways in neuroblastoma cell lines** Page 155  
*Federica Del Grosso; Marilena De Mariano; Lorena Passoni; Laura Paleari; Gian Paolo Tonini; Luca Longo*  
Italy
- POB32 Discovery of gene regulatory pathways implicated in neuroblastoma pathogenesis through integration of coding and non-coding gene expression and gene copy number data** Page 155  
*Katleen De Preter<sup>1</sup>; Annelies Fieuw<sup>1</sup>; Candy Kumps<sup>1</sup>; Pieter Mestdagh<sup>1</sup>; Bram De Wilde<sup>1</sup>; Alexander Schramm<sup>2</sup>; Johannes Schülte<sup>2</sup>; Rosa Noguera<sup>3</sup>; Angelika Eggert<sup>2</sup>; Jo Vandesompele<sup>1</sup>; Frank Speleman<sup>1</sup>*  
<sup>1</sup>Belgium; <sup>2</sup>Germany; <sup>3</sup>Spain
- POB33 The calcium-sensing receptor gene is inactivated by genetic and epigenetic mechanisms in neuroblastic tumors and its overexpression reduces neuroblastoma proliferation *in vitro* and *in vivo*** Page 156  
*Carmen de Torres; Carla Casalà; José Luis Ordóñez; Solange Miguel; Francina Munell; Patricia Galván; Eva Rodríguez; Gemma Mayol; Idoia García; Elisa Martí; Enrique de Alava; Cinzia Lavarino; Jaume Mora*  
Spain
- POB34 3D miRNA mutation screening in neuroblastoma** Page 156  
*Bram De Wilde<sup>1</sup>; Steve Lefever<sup>1</sup>; Pieter Mestdagh<sup>1</sup>; Nathalie Vanderstraeten<sup>1</sup>; Valerie Vanderstraeten<sup>1</sup>; Joachim De Schrijver<sup>1</sup>; Filip Pattyn<sup>1</sup>; Katleen De Preter<sup>1</sup>; Gert Van Peer<sup>1</sup>; Rogier Versteeg<sup>2</sup>; Ray Stallings<sup>3</sup>; Wim Van Criekinge<sup>1</sup>; Frank Speleman<sup>1</sup>; Jo Vandesompele<sup>1</sup>*  
<sup>1</sup>Belgium; <sup>2</sup>Netherlands; <sup>3</sup>Ireland

- POB35 Bmi-1 promotes neuroblastoma cell proliferation by regulation of cyclin levels** Page 156  
*Jane Ding; Ling Mao; Han-Fei Ding*  
 United States
- POB36 Prickle1: Possible tumour suppressive role in neuroblastoma** Page 156  
*Cecilia Dyberg; Panagiotis Papachristou; Thomas Ringstedt; Per Kogner; John Inge Johnsen*  
 Sweden
- POB37 X-linked Inhibitor of Apoptosis (XIAP) as a new target for NB therapy** Page 157  
*Georg Eschenburg; Patrick Hundsdoerfer; Holger N Lode*  
 Germany
- POB38 Focal amplifications and deletions at miRNA loci in neuroblastoma** Page 157  
*Annelies Fieuw<sup>1</sup>; Candy Kumps<sup>1</sup>; Steve Lefever<sup>1</sup>; Nadine Van Roy<sup>1</sup>; Pieter Mestdagh<sup>1</sup>; Johannes Schulte<sup>2</sup>; Alexander Schramm<sup>2</sup>; Angelika Eggert<sup>2</sup>; Rosa Noguera<sup>3</sup>; Anne De Paepe<sup>1</sup>; Jo Vandesompele<sup>1</sup>; Frank Speleman<sup>1</sup>; Katleen De Preter<sup>1</sup>*  
<sup>1</sup>Belgium; <sup>2</sup>Germany; <sup>3</sup>Spain
- POB39 Involvement of delta-like 1 homolog (drosophila) in the development of chemoresistance in neuroblastoma** Page 157  
*Marjorie Flahaut; Aurélie Coulon; Katya Nardou; Annick Mühlethaler-Mottet; Nicole Gross*  
 Switzerland
- POB40 Mechanisms of bHLH mediated neuronal differentiation** Page 157  
*Abraham Fong; Yi Cao; Zizhen Yao; Stephen Tapscott*  
 United States
- POB41 Nf-kB and IRF1, but not MYCN, control the expression of MHC class I and endoplasmic reticulum aminopeptidases in human neuroblastoma cells** Page 158  
*Matteo Forloni; Sonia Albini; Silvia Lorenzi; Loredana Cifaldi; Renata Boldrini; Giuseppe Giannini; Pier Giorgio Natali; Patrizio Giacomini; Doriana Fruci*  
 Italy
- POB42 Differential expression of PI3K-Akt pathway genes in neuroblastoma.** Page 158  
*Susanne Fransson; Frida Abel; Helena Eriksson; Tommy Martinsson; Katarina Ejeskär*  
 Sweden
- POB43 The impact of MYCN on the response to MDM2-p53 antagonists in neuroblastoma** Page 158  
*Laura D. Gamble<sup>1</sup>; Deborah A. Tweddle<sup>2</sup>; John Lunec<sup>2</sup>*  
<sup>1</sup>United Kingdom; <sup>2</sup>United Kingdom
- POB4 The role of MDMX on the response to MDM2-p53 antagonists in neuroblastoma** Page 158  
*Laura D. Gamble; Deborah A. Tweddle; John Lunec*  
 United Kingdom
- POB45 Distinctive expression patterns of MicroRNA in neuroblastoma tumors of opposite outcomes** Page 159  
*Charles-Henry Gattolliat; Guillaume Meurice; Matthieu Bauer; Laetitia Thomas; Bastien Job; Catherine Richon; Valérie Combaret; Philippe Dessen; Vladimir Lazar; Pierre Busson; Dominique Valteau-Couanet; Sétha Douc-Rasy; Jean Bénard*  
 France
- POB46 Neuroblastoma differentiation signalling pathways** Page 159  
*Dirk Geerts; Johan van Nes; Ingrid Revet; Gerda Huizenga; Nathalie Schilderink; Peter van Sluis; Jan Koster; Rogier Versteeg*  
 Netherlands
- POB47 The polyamine metabolism genes ornithine decarboxylase and antizyme 2 predict aggressive behavior in neuroblastomas with and without MYCN amplification** Page 159  
*Dirk Geerts<sup>1</sup>; Jan Koster<sup>1</sup>; David Albert<sup>2</sup>; Dana-Lynn Koomoa<sup>2</sup>; David Feith<sup>2</sup>; Anthony Pegg<sup>2</sup>; Richard Volckmann<sup>1</sup>; Huib Caron<sup>1</sup>; Rogier Versteeg<sup>1</sup>; Andre Bachmann<sup>2</sup>*  
<sup>1</sup>Netherlands; <sup>2</sup>United States

- POB48 Functional pRB loss is involved in impaired drug induced DNA damage response in *MYCN* amplified neuroblastoma cells** Page 159  
*Sina Gogolin; Daniel Dreidax; Gabriele Becker; Volker Ehemann; Manfred Schwab; Frank Westermann*  
*Germany*
- POB49 Modulation of neuroblastoma cell sensitivity towards anticancer drugs by MycN expression** Page 160  
*Vladimir Gogvadze; Bjorn Kruspig; Erik Norberg; Sten Orrenius; Boris Zhivotovsky*  
*Sweden*
- POB50 Epigenetic alterations in disseminated neuroblastoma: influence of *TMS1* gene hypermethylation in relapse risk** Page 160  
*Elena Grau; Adela Cañete; Yania Yañez; Francisco Martinez; Carmen Orellana; Silvestre Oltra; Rosa Noguera; Miguel Hernandez; Victoria Castel*  
*Spain*
- POB51 Combining peptide vaccination with immunostimulatory monoclonal antibodies provides potent immunotherapy in neuroblastoma**  
*Juliet Gray; Martin Glennie; Peter Johnson*  
*United Kingdom*
- POB52 Expression QTL analysis of tumor susceptibility in a mouse model of neuroblastoma** Page 160  
*Christopher Hackett; Pui Kwok; Song Young; Javed Khan; Balmain Allan; William A. Weiss*  
*United States*
- POB53 Age-dependent genotypes in aggressive neuroblastoma: *MYCN* amplification represents a few-hit/early-age form** Page 161  
*Fredrik Hedborg; Cihan Cetinkaya; Tommy Martinsson; Per Kogner; Jan Dumanski; Catarina Träger; Teresita Diaz deStåhl*  
*Sweden*
- POB54 Modeling the neuroblastoma tumor initiating cell microenvironment in 3D culture** Page 161  
*Anna Herland; Caroline Wigerup; Sofie Johansson; Sven Pålman; Ana I Teixeira*  
*Sweden*
- POB55 Epigenetically silenced microRNAs contribute to neuroblastoma pathogenesis** Page 161  
*Jasmien Hoebbeeck; Pieter Mestdagh; Filip Pattyn; Katleen De Preter; Ali Rihani; Joëlle Vermeulen; Tom Van Maerken; Steve Lefever; Justine Nuytens; Nurten Yigit; Anne De Paepe; Frank Speleman; Jo Vandesompele*  
*Belgium*
- POB56 The interaction between GRP75 and retinoic acid receptor- $\alpha$ /retinoid X receptor- $\alpha$  is essential for retinoic acid-induced neuronal differentiation of neuroblastoma cells** Page 161  
*Wen-Ming Hsu; Yu-Yin Shih; Hsinyu Lee; Hsueh-Fen Juan; Yeou-Guang Tsay; Yung-Feng Liao*  
*Taiwan*
- POB57 Neurod1 is involved in the development of neuroblastoma especially at initiation stage** Page 162  
*Peng Huang; Satoshi Kishida; Hitoshi Ichikawa; Kenji Kadomatsu*  
*Japan*
- POB58 An observation of chromosomal abnormalities and *MYCN* and *AURKA* gene changes in neuroblastoma patients** Page 162  
*Nihal Inandiklioglu; Sema Yilmaz; Osman Demirhan; Can Acipayam; Ibrahim Bayram; Fatih Erbey; Atila Tanyeli*  
*Turkey*
- POB59 Chromosomal instabilities in a neuroblastoma patient** Page 162  
*Nihal Inandiklioglu; Sema Yilmaz; Osman Demirhan; Ibrahim Bayram; Can Acipayam; Fatih Erbey; Atila Tanyeli*  
*Turkey*
- POB60 Constitutive *Hen2* expression in neural crest cells could be a trigger of neuroblastoma development** Page 162  
*Eriko Isogai; Miki Ohira; Seiki Haraguchi; Akira Nakagawara*  
*Japan*

- POB61 A novel orphan receptor, NLRR3, induces neuronal differentiation and is negatively regulated by MYCN and Miz-1 in neuroblastoma** Page 163  
*Akter Jesmin; Takatori Atsushi; Hossain Md. Shamim; Nakagawa Atsuko; Suenaga Yusuke; Islam Rafiqul; Nakagawara Akira*  
 Japan
- POB62 Comprehensive screen for genes involved in tumorigenesis and tumor-initiating cell formation in MYCN Tg mice** Page 163  
*Satoshi Kishida; Dong Liang Cao; Hitoshi Ichikawa; Kenji Kadomatsu*  
 Japan
- POB63 Common pathways in neuroblastoma and early-onset breast cancer** Page 163  
*Kenneth Kompass; Katherine Matthay; John Maris; John Witte*  
 United States
- POB64 Neuropeptide Y in neuroblastoma - Interactions with BDNF and effect on cell survival** Page 163  
*Anna Kuan-Celarier; Congyi Lu; Lindsay Everhart; Jeffrey Toretsky; Joanna Kitlinska*  
 United States
- POB65 Involvement of the CXCL12/CXCR4/CXCR7 axis in the malignant progression of human neuroblastoma** Page 164  
*Julie Liberman; Marjorie Flahaut; Annick Mühlethaler-Mottet; Aurélie Coulon; Jean-Marc Joseph; Nicole Gross*  
 Switzerland
- POB66 Mycn metabolic programs enforce glucose more than glutamine addiction in neuroblastoma cells** Page 164  
*Xueyuan Liu; Annette Vu; Michelle Gross; Stephen R. Master; Michael D. Hogarty*  
 United States
- POB67 Haploinsufficiency of candidate tumor suppressor gene CASZ1 blocks embryonic stem cell neurogenesis** Page 164  
*Zhihui Liu; Carol Thiele*  
 United States
- POB68 Screening of ALK mtations and abnormalities in neuroblastoma cell lines and Italian neuroblastoma cases** Page 164  
*Luca Longo; Marilena De Mariano; Federica Del Grosso; Lorena Passoni; Raffaella Defferrari; Katia Mazzocco; Aurora Castellano; Roberto Luksch; Alberto Garaventa; Gian Paolo Tonini*  
 Italy
- POB69 Ephrin/Eph signaling in neuroblastoma tumor initiating cells** Page 165  
*Vanessa Lundin; Ana Teixeira*  
 Sweden
- POB70 TRIM16 acts as a tumour suppressor via inhibitory effects on cytoplasmic vimentin and nuclear E2F1 in neuroblastoma cells** Page 165  
*Glenn Marshall; Jessica Bell; Jessica Koach; Owen Tan; Patrick Kim; Alena Malyukova; Wayne Thomas; Eric Sekyere; Tao Liu; Anne Cunningham; Vivienne Tobias; Murray Norris; Michelle Haber; Maria Kavallaris; Belamy Cheung*  
 Australia
- POB71 High-risk neuroblastoma without MYCN amplification - 11q-deletion tumors reveal a poor prognostic chromosome instability phenotype with later onset** Page 165  
*Tommy Martinsson; Helena Carén; Hanna Kryh; Rose-Marie Sjöberg; Jennie Erichsen; Maria Nethander; Catarina Tråger; Jonas Abrahamsson; Staffan Nilsson; Per Kogner*  
 Sweden
- POB72 Appearance of the novel activating F1174S ALK mutation in neuroblastoma correlates with disease progression, aggressive tumour behavior and unresponsiveness to therapy** Page 165  
*Tommy Martinsson; Jonas Abrahamsson; Therese Eriksson; Helena Carén; Magnus Hansson; Per Kogner; Sattu Kamaraj; Joel Weinmar; Kristina Ruuth; Ruth Palmer; Bengt Hallberg*  
 Sweden

- POB73 An integrative genomics screen uncovers ncRNA T-UCR functions in neuroblastoma tumours** Page 166  
*Pieter Mestdagh*<sup>1</sup>; *Erik Fredlund*<sup>2</sup>; *Filip Pattyn*<sup>1</sup>; *Ali Rihani*<sup>1</sup>; *Tom Van Maerken*<sup>1</sup>; *Joëlle Vermeulen*<sup>1</sup>; *Candy Kumps*<sup>1</sup>; *Bjorn Menten*<sup>1</sup>; *Katleen De Preter*<sup>1</sup>; *Alexander Schramm*<sup>3</sup>; *Johannes Schulte*<sup>3</sup>; *Rosa Noguera*<sup>4</sup>; *Gudrun Schleiermacher*<sup>5</sup>; *Isabelle Janoueix-Lerosey*<sup>5</sup>; *Geneviève Laureys*<sup>1</sup>; *Rob Powel*<sup>6</sup>; *David Nittner*<sup>1</sup>; *Jean-Christophe Marine*<sup>1</sup>; *Markus Ringnér*<sup>2</sup>; *Frank Speleman*<sup>1</sup>; *Jo Vandesompele*<sup>1</sup>  
<sup>1</sup>Belgium; <sup>2</sup>Sweden; <sup>3</sup>Germany; <sup>4</sup>Spain; <sup>5</sup>France; <sup>6</sup>United Kingdom
- POB74 Mir-17-92 is a master regulator of TGFβ-pathway activity in neuroblastoma** Page 166  
*Pieter Mestdagh*<sup>1</sup>; *Anna-Karin Boström*<sup>2</sup>; *Francis Impens*<sup>1</sup>; *Erik Fredlund*<sup>2</sup>; *Pasqualino De Antonellis*<sup>3</sup>; *Kris von Stedingk*<sup>2</sup>; *Bart Ghesquiere*<sup>1</sup>; *Gert Van Peer*<sup>1</sup>; *Chiara Medaglia*<sup>3</sup>; *Stefanie Schlierf*<sup>4</sup>; *Johannes Schulte*<sup>4</sup>; *Alexander Schramm*<sup>4</sup>; *Massimo Zollo*<sup>3</sup>; *Kris Gevaert*<sup>1</sup>; *Hakan Axelsson*<sup>2</sup>; *Frank Speleman*<sup>1</sup>; *Jo Vandesompele*<sup>1</sup>  
<sup>1</sup>Belgium; <sup>2</sup>Sweden; <sup>3</sup>Italy; <sup>4</sup>Germany
- POB75 Phosphoproteomic and expression analyses of a MYCN-amplified neuroblastoma cell line** Page 166  
*Kelly Mikan*; *Kolla Kristjansdottir*; *Alexandre Chlenski*; *Kelly Regan*; *Stephen X. Skapek*; *Samuel L. Volchenboum*  
 United States
- POB76 Analysis of cellular mediators of oncogenic signaling originating from activated ALK in neuroblastoma cells** Page 166  
*Izumi Miyake*; *Reiko Kamata*; *Hitoyasu Futami*; *Ryuichi Sakai*  
 Japan
- POB77 Development and characterization of ALK dependent cellular models** Page 167  
*Julie Mollet*; *Sarah Dubray*; *Virginie Raynal*; *Sophie Thomas*; *Heather Etchevers*; *Olivier Delattre*; *Isabelle Janoueix-Lerosey*  
 France
- POB78 Nucleotide excision repair and in vivo neuroblastoma chemoresistance to irinotecan** Page 167  
*Fabienne Munier*; *Marie Regairaz*; *Cathy Philippe*; *Marion Legentil*; *Vladimir Lazar*; *Gilles Vassal*  
 France
- POB79 A role of human Sgol1 on the growth of human neuroblastoma cells** Page 167  
*Yuko Murakami-Tonami*; *Satoshi Kishida*; *Kenji Kadomatsu*  
 Japan
- POB80 NF-kB signaling in neuroblastoma** Page 167  
*Natalia Nowakowska*; *Rogier Versteeg*; *Dirk Geerts*  
 Netherlands
- POB81 Activation of the transcription factor FOXO3/FKHRL1 by doxorubicin and etoposide induces reactive oxygen species production and programmed cell death in neuroblastoma cells** Page 168  
*Petra Obexer*; *Judith Hagenbuchner*; *Martin Hermann*; *Andrey Kuznetsov*; *Michael Ausserlechner*  
 Austria
- POB82 Histone deacetylase 10 contributes to the regulation of autophagy in neuroblastoma** Page 168  
*Ina Oehme*; *Jan-Peter Linke*; *Barbara C. Böck*; *Till Milde*; *Marco Lodrini*; *Matthias Fischer*; *Wilfried Roth*; *Sylvia Kaden*; *Hermann-Josef Gröne*; *Hedwig E. Deubzer*; *Olaf Witt*  
 Germany
- POB83 Aberrant activation of ALK kinase by a short form ALK protein in neuroblastoma** Page 168  
*Jun Okubo*; *Junko Takita*; *Riki Nishimura*; *Kentaro Ohki*; *Motohiro Kato*; *Yuyan Chen*; *Masashi Sanada*; *Akira Kikuchi*; *Takashi Igarashi*; *Yasuhide Hayashi*; *Seishi Ogawa*  
 Japan
- POB84 MYCN sensitizes human neuroblastoma cells to apoptosis by HIPK2 activation through a DNA damage response** Page 168  
*Marialaura Petroni*<sup>1</sup>; *Veronica Veschi*<sup>1</sup>; *Andrea Prodosmo*<sup>1</sup>; *Cinzia Rinaldo*<sup>1</sup>; *Isabella Massimi*<sup>1</sup>; *Maurizio Carbonari*<sup>1</sup>; *Carlo Dominici*<sup>1</sup>; *Heather McDowell*<sup>2</sup>; *Christian Rinaldi*<sup>1</sup>; *Isabella Screpanti*<sup>1</sup>; *Luigi Frati*<sup>1</sup>; *Armando Bartolazzi*<sup>1</sup>; *Alberto Gulino*<sup>1</sup>; *Silvia Soddu*<sup>1</sup>; *Giuseppe Giannini*<sup>1</sup>  
<sup>1</sup>Italy; <sup>2</sup>United Kingdom

- POB85 Expression of TWEAK/Fn14 in neuroblastoma; implications in apoptotic resistance and survival** Page 169  
*Ingvild Pettersen*<sup>1</sup>; *Ninib Baryawno*<sup>2</sup>; *Agnes Rasmuson*<sup>2</sup>; *Wenche Bakkeland*<sup>1</sup>; *Svetlana Zykova*<sup>1</sup>; *Jan-Olof Winberg*<sup>1</sup>; *Ugo Moens*<sup>1</sup>; *Per Kogner*<sup>2</sup>; *John Inge Johnsen*<sup>2</sup>; *Baldur Sveinbjörnsson*<sup>2</sup>  
<sup>1</sup>Norway; <sup>2</sup>Sweden
- POB86 Green Tea Catechins inhibit neuroblastoma growth in vitro and in vivo** Page 169  
*Izabela Piotrowska*; *Olesya Chayka*; *Sandra Cantilena*; *Arturo Sala*  
 United Kingdom
- POB87 N-myc gene expression: Impact on leukocyte infiltration in 3D neuroblastoma spheroids** Page 169  
*Maura Puppo*; *Florinda Battaglia*; *Claudio Gambini*; *Andrea Gregorio*; *Paolo Fardin*; *Luigi Varesio*  
 Italy
- POB88 Use of a microgravity culture system to assess biological behavior in neuroblastoma (NB) cell lines** Page 169  
*Robert Redden*; *Radhika Iyer*; *Laura Urbanski*; *Jane Minturn*; *Garrett Brodeur*; *Edward Doolin*  
 United States
- POB89 A biological link between p53 and MYCN/MYC expression in neuroblastoma** Page 170  
*Paul Lucas Regan*; *Robby Edo*; *Naohiko Ikegaki*; *Eric Rappaport*; *Xao Tang*  
 United States
- POB90 Mitochondria-related destabilization of MYC family proteins in neuroblastoma cells by OSU-03012, FCCP and Salinomycin** Page 170  
*Paul Lucas Regan*; *Autumn Fox*; *Jaime Torres*; *Joshua Jacobs*; *Makoto Horiuchi*; *Takayuki Itoh*; *Xao Tang*; *Naohiko Ikegaki*  
 United States
- POB91 Nutlin-3 induced miRNA expression changes in neuroblastoma cells** Page 170  
*Ali Rihani*; *Tom Van Maerken*; *Nurten Yigit*; *Justine Nuytens*; *Pieter Mestdagh*; *Frank Speleman*  
 Belgium
- POB92 Oncolytic effects of Sindbis virus on human neuroblastoma cells** Page 170  
*Eriko Saito*; *Tomoro Hishiki*; *Kengo Saito*; *Ayako Takenouchi*; *Takeshi Saito*; *Keita Terui*; *Yoshiharu Sato*; *Katsunori Kouchi*; *Hiroshi Shirasawa*; *Hideo Yoshida*  
 Japan
- POB93 A novel whole genome amplification approach is useful to perform aCGH in microdissected Schwannian Stromal and neuroblastic components of ganglioneuroblastomas** Page 171  
*Paola Scaruffi*<sup>1</sup>; *Simona Coco*<sup>1</sup>; *Francesca Valdora*<sup>1</sup>; *Sara Stigliani*<sup>1</sup>; *Yan Zhang*<sup>2</sup>; *Pengchin Chen*<sup>2</sup>; *John Smutko*<sup>2</sup>; *Gian Paolo Tonini*<sup>1</sup>  
<sup>1</sup>Italy; <sup>2</sup>United States
- POB94 Analysis of expression and inhibition of the Sonic Hedgehog signaling pathway in neuroblastoma** Page 171  
*Paula Schiapparelli*<sup>1</sup>; *Paula Lazcoz*<sup>1</sup>; *Tommy Martinsson*<sup>2</sup>; *John Inge Johnsen*<sup>2</sup>; *Per Kogner*<sup>2</sup>; *Javier S Castresana*<sup>1</sup>  
<sup>1</sup>Spain; <sup>2</sup>Sweden
- POB95 Anaplastic Lymphoma Kinase (ALK) activates the small GTPase Rap1 via the Rap1-specific GEF C3G in neuroblastoma** Page 171  
*Christina Schonherr*<sup>1</sup>; *Hai-Ling Yang*<sup>2</sup>; *Marc Vigny*<sup>3</sup>; *Ruth H. Palmer*<sup>1</sup>; *Bengt Hallberg*<sup>1</sup>  
<sup>1</sup>Sweden; <sup>2</sup>China; <sup>3</sup>France
- POB96 Deep sequencing of the small-RNA transcriptome reveals differential expression of microRNAs in high-risk versus low-risk neuroblastoma** Page 171  
*Johannes Schulte*<sup>1</sup>; *Tobias Marschall*<sup>1</sup>; *Marcel Martin*<sup>1</sup>; *Philipp Rosenstiel*<sup>1</sup>; *Pieter Mestdagh*<sup>2</sup>; *Stefanie Schlierf*<sup>1</sup>; *Theresa Thor*<sup>1</sup>; *Jo Vandesompele*<sup>2</sup>; *Angelika Eggert*<sup>1</sup>; *Stefan Schreiber*<sup>1</sup>; *Sven Rahmann*<sup>1</sup>; *Alexander Schramm*<sup>1</sup>  
<sup>1</sup>Germany; <sup>2</sup>Belgium

- POB97 Prognostic significance of NKp30 spliceoforms in neuroblastoma** Page 172  
*Michaela Semeraro-Kunz; Nicolas F. Delahaye; Véronique Minard-Colin; Clara Loecher; Sylvie Rusakiewicz; Laurence Zitvogel; Dominique Valteau-Couanet*  
 France
- POB98 Galectin-3 binding protein/90 kDa Mac-2 binding protein stimulates interleukin-6 expression in the neuroblastoma microenvironment** Page 172  
*Ayaka Silverman; Yasushi Fukaya; Hiroyuki Shimada; Susan Groshen; Robert Seeger; Yves DeClerck*  
 United States
- POB99 TrkAIII isoform expression is associated with aggressive behavior in human neuroblastomas (NBs)** Page 172  
*Anisha M. Simpson; Jennifer E. Light; Jane E. Minturn; Ruth Ho; Radhika Iyer; Carly R. Varela; Jennifer L. Mangino; Huaqing Zhao; Venkatadri Kolla; Garrett M. Brodeur*  
 United States
- POB100 Evaluation of MCPIP expression patterns and their impact on the survival of neuroblastoma cell lines** Page 172  
*Anna Skalniak; Danuta Mizgalska; Oksana Kovtonyuk; Jolanta Jura; Hanna Rokita*  
 Poland
- POB101 NLRR1, a direct target gene of MYCN, modulates aggressive growth of neuroblastoma by selectively enhancing EGF and IGF signals through the components of lipid rafts** Page 173  
*Atsushi Takatori; MD. Shamim Hossain; Jesmin Akter; Atsushi Ogura; Yohko Nakamura; Akira Nakagawara*  
 Japan
- POB102 Aurora A kinase is a possible target of OSU-03012 to destabilize MYC family proteins** Page 173  
*Yutaka Tamura<sup>1</sup>; Naohiko Ikegaki<sup>2</sup>*  
<sup>1</sup>Japan; <sup>2</sup>United States
- POB103 Expression and function of RET in neuroblastoma (NB) cell lines** Page 173  
*Laura H Tetri; Ruth Ho; Anisha M Simpson; Radhika Iyer; Jane E Minturn; Garrett M Brodeur*  
 United States
- POB104 Irrespective of ALK mutational status, neuroblastoma tumors are sensitive to Akt inhibitor perifosine** Page 173  
*Carol Thiele; Zhijie Li*  
 United States
- POB105 Enhanced effect of IFN $\gamma$  on the induced-apoptosis of neuroblastoma cells by cytotoxic drugs** Page 174  
*Haixia Tong; Jinhua Zhang*  
 China
- POB106 JAGGED1 antagonizes NOTCH2 mediated cell migration** Page 174  
*Tim van Groningen; Marloes Broekmans; Nurdan Akogul; Rogier Versteeg; Johan van Nes*  
 Netherlands
- POB107 A migration signature in neuroblastoma cell lines and tumours identifies YAP1 as a regulator of cell migration** Page 174  
*Johan van Nes; Mireille Indemans; Nurdan Akogul; Jan Koster; Rogier Versteeg*  
 Netherlands
- POB108 Functional microRNA library screen to identify synthetically lethal interactions in neuroblastoma** Page 174  
*Gert Van Peer; Pieter Mestdag; Frank Speleman; Jo Vandesompele*  
 Belgium
- POB109 Galectin-3 protects MYCN single copy neuroblastoma cells from apoptosis: a mechanism impaired by MYCN** Page 175  
*Veronica Veschi<sup>1</sup>; Marialaura Petroni<sup>1</sup>; Isabella Massimi<sup>1</sup>; Carlo Dominici<sup>1</sup>; Heather P. McDowell<sup>2</sup>; Isabella Screpanti<sup>1</sup>; Luigi Frati<sup>1</sup>; Armando Bartolazzi<sup>1</sup>; Alberto Gulino<sup>1</sup>; Giuseppe Giannini<sup>1</sup>*  
<sup>1</sup>Italy; <sup>2</sup>United Kingdom

- POB110 Genome-wide analysis of favorable-stage neuroblastoma reveals discrete patterns of gene expression and alternative splicing between MYCN amplified and non-amplified tumors** Page 175  
*Samuel L. Volchenbourn; Susan L. Cohn; Rani E. George*  
United States
- POB111 JAG2 induction in hypoxic tumor cells alters Notch signaling and enhances endothelial cell tube formation** Page 175  
*Kristoffer von Stedingk; Alexander Pietras; David Lindgren; Sven Pahlman; Axelson Hakan*  
Sweden
- POB112 Transcriptome analysis of chromosome 1p in neuroblastoma** Page 175  
*Wenchao Wang; Yanan Kuang; Robert Distel; Rani E. George*  
United States
- POB113 Expressional alterations in ultra-conserved non-coding RNA resulting from changes in MYCN levels and in response to ATRA-induced differentiation** Page 176  
*Karen Watters; Kenneth Bryan; Niamh Foley; Ray Stallings*  
Ireland
- POB114 ALK signaling in neuroblastoma** Page 176  
*Ellen Westerhout; Peter Stroeken; Huib Caron; Rogier Versteeg*  
Netherlands
- POB115 Regulation of differentiation by estrogen receptors in neuroblastoma cells** Page 176  
*Ulrica Westermark; Jakob Lovén; Inga Müller; Marie Arsenian Henriksson*  
Sweden
- POB116 Role of p53 and p73 in neuroblastoma chemosensitivity and neuroblastoma tumor initiating cells (TIC)** Page 176  
*Jennifer Wolter; David Malkin; Meredith Irwin*  
Canada
- POB117 Identification of proteomic changes associated with differentiated neuroblastoma using an in vitro differentiation system and an optimized proteomics platform based on <sup>18</sup>O peptide labeling** Page 177  
*Chen Yin; Wen-Ming Hsu; Yeou-Guang Tsay*  
Taiwan
- POB118 Role of Caspase 8 and Caspase 3 in TRAIL-induced apoptosis of neuroblastoma cells** Page 177  
*Jinhua Zhang; Haixia Tong*  
China
- POB119 Creation of a CHD5 knockout (KO) mouse model** Page 177  
*Tiangang Zhuang; Venkatadri Kolla; Tobias Raabe; Hiroshi Koyama; Mayumi Higashi; Peter S. White; Garrett M. Brodeur*  
United States

### Posters – Translational

- POT1 Prognostic significance of tumor and microenvironment gene expression for children with metastatic MYCN non-amplified neuroblastoma** Page 178  
*Shahab Asgharzadeh<sup>1</sup>; Jill Salo<sup>1</sup>; Lingyun Ji<sup>1</sup>; Cathy Wei Yao Liu<sup>1</sup>; Roger Pique-Regi<sup>1</sup>; Andre Oberthuer<sup>2</sup>; Matthias Fischer<sup>2</sup>; Yue-Xian Tu<sup>1</sup>; Leonid Metelitsa<sup>1</sup>; Wendy London<sup>1</sup>; Hiroyuki Shimada<sup>1</sup>; Frank Berthold<sup>2</sup>; Richard Sposto<sup>1</sup>; Robert C. Seeger<sup>1</sup>*  
<sup>1</sup>United States; <sup>2</sup>Germany
- POT2 Genomic characterization and targeted resequencing of high-risk neuroblastoma (the neuroblastoma TARGET)** Page 178  
*Edward F. Attiyeh; Michael D. Hogarty; Yaël P. Mossé; Sharon J. Diskin; Hakon Hakonarson; Shahab Asgharzadeh; Richard Sposto; Wendy B. London; Julie M. Gastier-Foster; Daniela S. Gerhard; Malcolm A. Smith; Jinghui Zhang; Javed Khan; Robert C. Seeger; John M. Maris*  
United States

- POT3 Identification of miRNAs contributing to neuroblastoma chemoresistance** Page 178  
*Duncan Ayers*<sup>1</sup>; *Pieter Mestdagh*<sup>2</sup>; *Ali Rihani*<sup>2</sup>; *Alexander Schramm*<sup>3</sup>; *Martin Michaelis*<sup>3</sup>; *Jindrich Cinatl Jr.*<sup>3</sup>; *Angelika Eggert*<sup>3</sup>; *Philip J Day*<sup>1</sup>; *Frank Speleman*<sup>2</sup>; *Tom Van Maerken*<sup>2</sup>; *Jo Vandesompele*<sup>2</sup>  
<sup>1</sup>United Kingdom; <sup>2</sup>Belgium; <sup>3</sup>Germany
- POT4 Gene expression signatures of mutant ALK in neuroblastoma** Page 179  
*Anna Azarova*; *Kenneth Ross*; *James Christensen*; *Kimberley Stegmaier*; *Rani E. George*  
 United States
- POT5 Cytomegalovirus infection in neuroblastoma, high prevalence in tumors and reduced growth in vivo and in vitro using HCMV targeted therapies** Page 179  
*Ninib Baryawno*; *Nina Wolmer-Solberg*; *Dieter Fuchs*; *Lonneke Verboon*; *Afsar Rahbar*; *Lova Segerstrom*; *Baldur Sveinbjornsson*; *John-Inge Johnsen*; *Per Kogner*; *Cecilia Soderberg-Nauclér*  
 Sweden
- POT6 Inhibition of lipoxygenases promotes retinoic acid induced cell death in neuroblastoma** Page 179  
*Emma Bell*; *Frida Ponthan*; *Huw Thomas*; *Kieran O'Toole*; *Penny, E Lovat*; *John Lunec*; *Deborah, A Tweddle*; *Christopher, P.F, Redfern*  
 United Kingdom
- POT7 Prognosis approach of one segmental chromosome aberration in neuroblastoma** Page 179  
*Ana P. Berbegall*; *Eva Villamon*; *Marta Piqueras*; *Irene Tadeo*; *Adela Cañete*; *Samuel Navarro*; *Victoria Castel*; *Cañete*; *Rosa Noguera*  
 Spain
- POT8 Relationship between ALK expression and genetic predictive factors in neuroblastoma** Page 180  
*Arnaud Berthier*; *Marta Piqueras*; *Eva Villamon*; *Ana P. Berbegall*; *Irene Tadeo*; *Victoria Castel*; *Samuel Navarro*; *Rosa Noguera*  
 Spain
- POT9 POTential role of mesenchymal stromal cells in experimental neuroblastoma treatment** Page 180  
*Giovanna Bianchi*; *Laura Emionite*; *Fabio Morandi*; *Daga Antonio*; *Michele Cilli*; *Lizzia Raffaghello*; *Vito Pistoia*  
 Italy
- POT10 Combinatory effect of 5-AZA-cytidin and Octreotide on neuroblastoma cell proliferation and apoptosis** Page 180  
*Peyman Björklund*; *Anna Oskarsson*; *Per Hellman*  
 Sweden
- POT11 ALK and PHOX2B mutations in neuroblastic tumours with highly suspected predisposition: Rare events and unexpected clinical features** Page 180  
*Franck Bourdeaut*; *Agnes Ribeiro*; *Marion Gauthier-Villars*; *Jean Michon*; *Yves Perel*; *Gudrun Schleiermacher*; *Jeanne Amiel*; *Gaëlle Pierron*; *Isabelle Janoueix-Lerosey*; *Olivier Delattre*  
 France
- POT12 TLR9 expression and functionality in neuroblastoma delineate a novel prognostic marker and therapeutic target** Page 181  
*Chiara Brignole*; *Danilo Marimpietri*; *Daniela Di Paolo*; *Fabio Morandi*; *Fabio Pastorino*; *Alessia Zorzoli*; *Gabriella Pagnan*; *Monica Loi*; *Irene Caffa*; *Giuseppe Erminio*; *Riccardo Haupt*; *Claudio Gambini*; *Patrizia Perri*; *Vito Pistoia*; *Mirco Ponzoni*  
 Italy
- POT13 Arguments for the intravenous application of high dose ascorbic acid for treatment of neuroblastoma** Page 181  
*Gernot Bruchelt*; *Beate Deubzer*; *Florian Mayer*; *Zyrafete Kuci*; *Marena Niewisch*; *Rupert Handgretinger*  
 Germany
- POT14 Molecular imaging of MYCN-amplified neuroblastoma tumorigenesis in orthotopic xenograft and transgenic TH-MYCN murine models** Page 181  
*Erika Cantelli*<sup>1</sup>; *Antonio Fasci*<sup>1</sup>; *Carmelo Quarta*<sup>1</sup>; *Laura Mezzanotte*<sup>1</sup>; *Salvatore Serravalle*<sup>1</sup>; *Korinne Di Leo*<sup>1</sup>; *Cristina Nanni*<sup>1</sup>; *Stefano Fanti*<sup>1</sup>; *Aldo Roda*<sup>1</sup>; *William A Weiss*<sup>2</sup>; *Patrizia Hrelia*<sup>1</sup>; *Andrea Pession*<sup>1</sup>; *Roberto Tonelli*<sup>1</sup>  
<sup>1</sup>Italy; <sup>2</sup>United States

- POT15 Microarray-based pathway analysis leads to the identification of POTential molecular mechanisms underlying gamma-secretase inhibitor-induced neuronal differentiation of neuroblastoma cells** Page 182  
*Hsiu-Hao Chang; Wen-Ming Hsu; Hsueh-Fen Juan; Yung-Feng Liao; Min-Chuan Huang; Hsinyu Lee; Fon-Jou Hsieh; Kai-Hsin Lin*  
 Taiwan
- POT16 IL-21-based immunotherapy of neuroblastoma in combination with lymphodepleting antibodies** Page 182  
*Michela Croce; Anna Maria Orengo; Antonella Brizzolara; Valentina Rigo; Barbara Carlini; Maria Valeria Corrias; Silvano Ferrini*  
 Italy
- POT17 Characterisation of tumour progression, vascularisation and response to chemotherapy in transgenic mouse models of Neuroblastoma (TH-MYCN and TH-MYCN/p53ER<sup>tam</sup>) using magnetic resonance imaging** Page 182  
*Elizabeth Cullis<sup>1</sup>; Yann Jamin<sup>2</sup>; Lynsey Vaughan<sup>2</sup>; Sergey Popov<sup>2</sup>; Dow-Mu Koh<sup>1</sup>; Andrew Pearson<sup>1</sup>; Louis Chesler<sup>1</sup>; Simon Robinson<sup>1</sup>*  
<sup>1</sup>United Kingdom; <sup>2</sup>United Kingdom
- POT18 Development and characterization of bioluminescent orthotopic and metastatic neuroblastoma models** Page 182  
*Estelle Daudigeos-Dubus; Valérie Rouffiac; Ingrid Leguerney; Yann Monnet; Paule Opolon; Olivia Bawa; Birgit Geoerger; Gilles Vassal*  
 France
- POT19 The DNA-binding protein, YB-1 is a direct N-Myc target and influences repair and resistance in neuroblastoma cell lines** Page 183  
*Stephanie Degen; Steffi Kuhfittig-Kulle; Johannes H. Schulte; Frank Westermann; Alexander Schramm; Angelika Eggert; Kathy Astrahantseff*  
 Germany
- POT20 Comparative interactomics, transcriptomics and proteomics studies of CDK inhibitors roscovitine and CR8 effects on human neuroblastoma SH-SY5Y cells converge to a central role of Myc** Page 183  
*Claire Delehouze; Nadège Loaec; Nathalie Desban; Laurent Meijer*  
 France
- POT21 ALK and pALK protein levels in NBL cell lines correlate with ALK mutation status and responsiveness to ALK inhibition** Page 183  
*Floor Duijkers; Jose Gaal; Pieter Admiraal; Rob Pieters; Jules Meijerink; Ronald Krijger, de; Max Noesel*  
 Netherlands
- POT22 Development of a DNA methylation array normalization method for analyzing demethylating treatment effects in paired neuroblastoma cell lines** Page 183  
*Floor Duijkers; Maarten Iterson, van; Jules Meijerink; Pieter Admiraal; Rob Pieters; Judith Boer, de; Renee Menezes, de; Max Noesel, van*  
 Netherlands
- POT23 Expression of chemokine CCL21 and its receptor CCR7 in in neuroblastoma** Page 184  
*Josiah Dungwa; Urmila Uparkar; David Bates; Pramila Ramani*  
 United Kingdom
- POT24 Abstract withdrawn**
- POT25 Hypoxia gene signature as a prognostic factor in neuroblastoma patients** Page 184  
*Paolo Fardin<sup>1</sup>; Andrea Cornero<sup>1</sup>; Massimo Acquaviva<sup>1</sup>; Annalisa Barla<sup>1</sup>; Sofia Mosci<sup>1</sup>; Rogier Versteeg<sup>2</sup>; Jan J. Molenaar<sup>2</sup>; Ingrid Ora<sup>2</sup>; Huib N. Caron<sup>2</sup>; Luigi Varesio<sup>1</sup>*  
<sup>1</sup>Italy; <sup>2</sup>Netherlands
- POT26 Analysis of cytotoxic drugs that selectively target cells with MYC overexpression** Page 184  
*Anna Frenzel; Ami Albiñ; Hanna Zirath; Marina Vita; Marie Arsenian Henriksson*  
 Sweden

- POT27 Expression of the neuron-specific protein CHD5 is an independent marker of outcome in neuroblastoma** Page 185  
*Idoia Garcia*<sup>1</sup>; *Gemma Mayol*<sup>1</sup>; *Eva Rodríguez*<sup>1</sup>; *Mariona Suñol*<sup>1</sup>; *Timothy Gershon*<sup>1</sup>; *José Ríos*<sup>1</sup>; *Nai-Kong Cheung*<sup>2</sup>; *Carmen de Torres*<sup>1</sup>; *Mark Kieran*<sup>2</sup>; *Jaume Mora*<sup>1</sup>; *Cinzia Lavarino*<sup>1</sup>  
<sup>1</sup>Spain; <sup>2</sup>United States
- POT28 Sphingosine-1-phosphate signaling is a mechanism of fenretinide resistance and provides a novel therapeutic target** Page 185  
*Matthew V Ghent*; *Taylor Chen*; *Youngeem Kim*; *Ana Jakimenko*; *Min Kang*; *C. Patrick Reynolds*  
 United States
- POT29 Omega-3 fatty acid supplementation delays the progression of neuroblastoma *in vivo*** Page 185  
*Helena Gleissman*<sup>1</sup>; *Lova Segerström*<sup>1</sup>; *Mats Hamberg*<sup>1</sup>; *Frida Ponthan*<sup>2</sup>; *Magnus Lindskog*<sup>1</sup>; *John Inge Johnsen*<sup>1</sup>; *Per Kogner*<sup>1</sup>  
<sup>1</sup>Sweden; <sup>2</sup>United Kingdom
- POT30 'BH3 profiles' identify neuroblastomas with exquisite ABT-737/chemotherapy *in vivo* and Bim signaling is a critical determinant sensitivity** Page 185  
*Kelly C. Goldsmith*; *Michelle Gross*; *Xueyuan Liu*; *Susan K. Peirce*; *Chengyu Prince*; *Annette Vu*; *Niel Chen*; *C. Patrick Reynolds*; *Michael D. Hogarty*  
 United States
- POT31 Cepharanthine reverses multidrug resistance and sensitizes neuroblastoma cells to vincristine-induced cell death** Page 186  
*Regina Graham*; *John Thompson*; *James Guest*; *Keith Webster*; *Steven Vanni*  
 United States
- POT32 ATM deletion is a frequent event in neuroblastoma** Page 186  
*F Gumy-Pause*<sup>1</sup>; *H Ozsahin*<sup>1</sup>; *M Khoshbeen-Boudal*<sup>1</sup>; *B Pardo*<sup>1</sup>; *DR Betts*<sup>2</sup>; *P Maillet*<sup>1</sup>; *MD Hogarty*<sup>3</sup>; *EF Attiyeh*<sup>3</sup>; *AP Sappino*<sup>1</sup>  
<sup>1</sup>Switzerland; <sup>2</sup>Ireland; <sup>3</sup>United States
- POT33 Computer vision in neuroblastoma: computer-aided prognosis** Page 186  
*Metin Gurcan*; *Olcay Sertel*; *Hiroyuki Shimada*  
 United States
- POT34 Analysis of aggressive human and mouse ALK neuroblastoma mutations** Page 186  
*Bengt Hallberg*; *Sattu Kamaraj*; *Christina Schönherr*; *Kristina Ruuth*; *Cecilia Axelsson*; *Ruth Palmer*  
 Sweden
- POT35 Rapamycin upregulates osteoprotegerin and increases time to pathologic fracture in a mouse neuroblastoma bone metastasis model** Page 187  
*Joseph Hartwich*; *Adrienne Myers*; *Cathy Ng*; *Andrew M Davidoff*  
 United States
- POT36 The addition of HIF inhibition POTentiates the effects of angiogenesis inhibition in mouse neuroblastoma xenografts** Page 187  
*Joseph Hartwich*; *Yunyu Spence*; *Cathy Ng*; *Christopher Morton*; *Andrew M Davidoff*  
 United States
- POT37 Screening at 18 months of age using the new serum marker for reducing the mortality of neuroblastoma: Simulation using Japanese population based cohort study** Page 187  
*Eiso Hiyama*; *Arata Kamimatsuse*; *Naomi Kamei*; *Tsutomu Masujima*; *Keiko Hiyama*; *Megu Ohtaki*  
 Japan
- POT38 Effect Phosphoinositide-3-Kinase (PI3K) and mTOR dual inhibitors in Human Neuroblastomas (NBs)** Page 187  
*Ruth Ho*; *Jane Minturn*; *Valerie Brown*; *Radhika Iyer*; *Cecilia Sheen*; *Jessica Hulitt*; *Anisha Simpson*; *Carly Varela*; *Jennifer Mangino*; *Venkatadri Kolla*; *Garrett Brodeur*  
 United States
- POT39 Analysis of molecular interactions between the GD2 ganglioside-specific mouse monoclonal antibody 14G2a and GD2-mimicking peptides** Page 188  
*Irena Horwacik*; *Aleksandra Kowalczyk*; *Malgorzata Bzowska*; *Dominik Czaplicki*; *Hanna Rokita*  
 Poland

- POT40 NLRR2 is a novel regulator of neuroblastoma cell death via ER stress** Page 188  
*Shamim Hossain; Atsushi Takatori; Jesmin Akter; Kamrul Hasan; Akira Nakagawara*  
 Japan
- POT41 Positive feedback loop of Mycn-nlrr1-egf/egfr signals in aggressive neuroblastomas to accelerate cell growth** Page 188  
*Shamim Hossain; Atsushi Takatori; Jesmin Akter; Yusuke Suenaga; Toshinori Ozaki; Akira Nakagawara*  
 Japan
- POT42 Application of chicken anti-human midkine IgY antibody to neuroblastoma diagnosis** Page 188  
*Shinya Ikematsu; Shoma Tsubota; Chika Yamashiro; Satoshi Kishida; Yukio Yuzawa; Akira Nakagawara; Kenji Kadomatsu*  
 Japan
- POT43 Expression and gene status of HER2 in neuroblastic tumors** Page 189  
*Ewa Izycka-Swieszewska<sup>1</sup>; Agnieszka Wozniak<sup>2</sup>; Jacek Kot<sup>1</sup>; Wieslawa Grajkowska<sup>1</sup>; Elzbieta Drozynska<sup>1</sup>; Anna Balcerska<sup>1</sup>; Danuta Perek<sup>1</sup>; Bozena Dembowska<sup>1</sup>; Janusz Limon<sup>1</sup>*  
<sup>1</sup>Poland; <sup>2</sup>Belgium
- POT44 Ki-67 proliferation index is marker of poor prognosis in neuroblastoma especially in patients aged over 18 months** Page 189  
*Ewa Izycka-Swieszewska; Beata Stefania Lipska; Elzbieta Drozynska; Anna Balcerska; Danuta Perek; Wieslawa Grajkowska; Bozena Dembowska; Teresa Klepacka; Wojciech Wozniak; Alicja Chybicka; Janusz Limon*  
 Poland
- POT45 MLPA (Multiplex Ligation-dependent Probe Amplification) and FISH comparison/validation for genetic characterization of neuroblastoma** Page 190  
*Marta Jeison; Gili Halevy-Berko; Galina Feinberg-Gorenshtein; Svetlana Itskovitch; Shifra Ash; Jack Mardouck; Drorit Luria; Jerry Stein; Batia Stark; Smadar Avigad; Isaac Yaniv*  
 Israel
- POT46 Prolonged low-dose administration of the cyclooxygenase-2 inhibitor celecoxib enhances the antitumor activity of irinotecan against neuroblastoma xenografts** Page 190  
*Setsuko Kaneko; Michio Kaneko*  
 Japan
- POT47 CHD5 is part of the nucleosome remodeling and histone deacetylase (NuRD) complex in neuroblastoma (NB) cell lines** Page 190  
*Venkatadri Kolla; Tiangang Zhuang; Hiroshi Koyama; Koumudi Naraparaju; Mayumi Higashi; Gerd A. Blobel; Peter S. White; Garrett M. Brodeur*  
 United States
- POT48 Mechanisms of CHD5 inactivation in neuroblastomas** Page 190  
*Hiroshi Koyama; Tiangang Zhuang; Jennifer E. Light; Venkatadri Kolla; Mayumi Higashi; Wendy B. London; Garrett M. Brodeur*  
 United States
- POT49 Neuroblastoma cell lines, phenotype and susceptibility towards natural killer cells** Page 191  
*Kathelijne CJM Kraal; MM Ostaijen ten Dam; LM Ball; MJD van Tol; RM Egeler*  
 Netherlands
- POT50 UCHL1-Upregulation correlates with reduction of vital neuroblastoma cells by fenretinide and doxorubicin treatment** Page 191  
*Sandra Kuehnel; Grigore Cernaianu; Kai Stuehler; Helmut Meyer; Albrecht Bufe; Manfred Koeller; Barbara Sitek; Ralf-Bodo Troebs*  
 Germany
- POT51 Low dose metronomic (LDM) administration of oral to POTecan and pazopanib as an effective preclinical antiangiogenic therapy in neuroblastoma** Page 191  
*Sushil Kumar; Reza Mokhtari; Bing Wu; Libo Zhang; Shan Mann; Robert Kerbel; Herman Yeger; Sylvain Baruchel*  
 Canada

- POT52 Clinical significance of TRK family gene expression in neuroblastomas** Page 191  
*Jennifer E. Light; Hiroshi Koyama; Eli Gordin; Jane E. Minturn; Radhika Iyer; Ruth Ho; Anisha M. Simpson; Venkatadri Kolla; Patrick W. McGrady; Wendy B. London; Garrett M. Brodeur*  
*United States*
- POT53 Cancelled**
- POT54 Induction of miR-183 via an epigenetic mechanism suppresses neuroblastoma malignancy** Page 192  
*Marco Lodrini; Johannes H. Schulte; Mirco Castoldi; Ina Oehme; Martina Muckenthaler; Olaf Witt; Hedwig E. Deubzer*  
*Germany*
- POT55 Telomere elongation and chromosomal instability in non-MYCN amplified clinically aggressive neuroblastoma** Page 192  
*Gisela Lundberg<sup>1</sup>; John-Kalle Lämsberg<sup>1</sup>; Alexander Pietras<sup>1</sup>; Sven Pålman<sup>1</sup>; Attila Frigyesi<sup>1</sup>; Victoria Castel<sup>2</sup>; Samuel Navarro<sup>2</sup>; Marta Piqueras<sup>2</sup>; Rosa Noguera<sup>2</sup>; Tommy Martinsson<sup>1</sup>; David Gisselsson<sup>1</sup>*  
<sup>1</sup>Sweden; <sup>2</sup>Spain
- POT56 Nanoparticle (NP) delivery of the Trk inhibitor lestaurtinib in neuroblastomas (NBs)** Page 192  
*Jennifer Mangino; Radhika Iyer; Michael Chorny; Ivan Alferiev; Jane Minturn; Ruth Ho; Anisha Simpson; Carly Varela; Audrey Evans; Robert Levy; Garrett Brodeur*  
*United States*
- POT57 Bio-molecular and histo-pathological characterization of Neuroblastoma (NB) in adolescent and young adults (AYA). Italian experience with 33 cases** Page 192  
*Katia Mazzocco; Raffaella Defferrari; Claudio Gambini; Angela Rita Sementa; Alberto Garaventa; Gian Paolo Tonini; Massimo Conte*  
*Italy*
- POT58 Inhibition of PARP-1 enhances the efficacy of [131I]MIBG/To POTecan combinations in vitro** Page 193  
*Anthony G McCluskey<sup>1</sup>; Annette Sorensen<sup>1</sup>; Mathias Tesson<sup>2</sup>; Robert J Mairs<sup>2</sup>; Marie Boyd<sup>1</sup>*  
<sup>1</sup>United Kingdom; <sup>2</sup>United Kingdom
- POT59 CDK inhibitors Roscovitine and CR8 trigger Mcl-1 Down-regulation and apoptotic cell death in neuroblastoma cells** Page 193  
*Laurent Meijer; Claire Delehouze; Nadège Loaec*  
*France*
- POT60 Preclinical testing of novel kinase inhibitors in high-risk neuroblastoma** Page 193  
*Ebba Palmberg; Linda Rickardson; Malin Wickstrom; Magnus Lindskog; John Inge Johnsen; Per Kogner*  
*Sweden*
- POT61 Balance of pro- versus anti-angiogenic splice isoforms of vascular endothelial growth factor as a regulator of neuroblastoma growth** Page 193  
*Maria Peiris<sup>1</sup>; David Owen Bates<sup>1</sup>; Pramila Ramani<sup>2</sup>*  
<sup>1</sup>United Kingdom; <sup>2</sup>United Kingdom
- POT62 Predictive consequences of risk stratification neuroblastoma patients using FISH on TMAP** Page 194  
*Marta Piqueras; Samuel Navarro; Adela Cañete; Victoria Castel; Rosa Noguera*  
*Spain*
- POT63 The effect of COX-2 expression on celecoxib sensitivity and tumour growth in neuroblastoma** Page 194  
*Frida Ponthan; Emma Bell; C.P.F Redfern*  
*United Kingdom*
- POT64 Targeting neuroblastoma and neuroblastoma tumour initiating cells with the oncolytic viruses myxoma and vesicular stomatitis virus** Page 194  
*Nicole Redding<sup>1</sup>; Loen Hansford<sup>1</sup>; David Kaplan<sup>1</sup>; Grant McFadden<sup>2</sup>; John Bell<sup>1</sup>; Steve Robbins<sup>1</sup>; Paul Beaudry<sup>1</sup>*  
<sup>1</sup>Canada; <sup>2</sup>United States

- POT65 Survival pathways of high-risk neuroblastoma identified by functional genomics** Page 194  
*Lauren Richard; James Annis; Carla Grandori; Julie Park*  
 United States
- POT66 Anti-angiogenic activity of the selective VEGFR-1, -2, -3 inhibitor Axitinib (AG-013736) in human neuroblastoma xenografts** Page 195  
*Jochen Rössler<sup>1</sup>; Yann Monnet<sup>2</sup>; Françoise Farace<sup>2</sup>; Paule Opolon<sup>2</sup>; Estelle Daudigeos-Dubus<sup>2</sup>; Fabienne Munier<sup>2</sup>; Gilles Vassal<sup>2</sup>; Birgit Georger<sup>2</sup>*  
<sup>1</sup>Germany; <sup>2</sup>France
- POT67 Relationship between ploidy and genetic instability of neuroblastoma in children below 18 months of age** Page 195  
*Irene Tadeo; Amparo Ruiz-Sauri; Marta Piqueras; Eva Villamon; Ana P. Berbegall; Adela Cañete; Victoria Castel; Samuel Navarro; Rosa Noguera*  
 Spain
- POT68 Bi-directional regulation of the wild type of ALK in neuroblastoma: Its high expression in stage 4s tumors and transcriptional activation by MYCN and Sp1** Page 195  
*Atsushi Takatori; Heggo Asmaa; Ajjur Rahman; Kamrul Hasan; Daisuke Takagi; Yasutoshi Tatsumi; Miki Ohira; Shamim Hossain; Jesmin Akter; Atsuko Nakagawa; Akira Nakagawara*  
 Japan
- POT69 CD133 regulates signal transduction pathways and prevents differentiation via RET suppression in neuroblastoma cells** Page 195  
*Hisanori Takenobu; Osamu Shimozato; Hidemasa Ochiai; Yohko Yamaguchi; Miki Ohira; Akira Nakagawara; Takehiko Kamijo*  
 Japan
- POT70 Dendritic cell-based immunotherapy using sendai virus vector - a preclinical efficacy study against neuroblastoma: An advanced report** Page 196  
*Sakura Tanaka; Tatsuro Tajiri; Yoshikazu Yonemitsu; Kyosuke Tatsuta; Ryota Souzaki; Yasuji Ueda; Yuki Koga; Aiko Suminoe; Toshiro Hara; Mamoru Hasegawa; Tomoaki Taguchi*  
 Japan
- POT71 DD3, a large non-coding RNA against the pro-apoptotic BMCC1 gene, is a candidate target for treating neuroblastoma** Page 196  
*Yasutoshi Tatsumi; Tomoaki Yokoyama; Myat Lin Ooo; Ryo Takano; Daisuke Takagi; Miki Ohira; Akira Nakagawara*  
 Japan
- POT72 The novel PDK1 inhibitor OSU03012 and the dual PI3K/mTOR inhibitor PI103 target high-risk neuroblastoma in vitro and in vivo** Page 196  
*Lova Segerström; Ninib Baryawno; Baldur Sveinbjörnsson; Lotta Elfman; Per Kogner; John Inge Johnsen*  
 Sweden
- POT73 NK cells engineered to express the chimeric receptor scFv(ch14.18)-zeta specifically lyse GD2 expressing neuroectodermal tumors** Page 196  
*Diana Seidel<sup>1</sup>; Nicole Huebener<sup>2</sup>; Tina Mueller<sup>1</sup>; Doerthe Pferdmenges<sup>1</sup>; Anastasia Shibina<sup>2</sup>; Torsten Tonn<sup>1</sup>; Ulrike Koehl<sup>1</sup>; Ruth Esser<sup>1</sup>; Winfried S. Wels<sup>1</sup>; Holger N. Lode<sup>1</sup>*  
<sup>1</sup>Germany; <sup>2</sup>United States
- POT74 Synergistic inhibition of neuroblastoma tumor development by targeting ornithine decarboxylase and topoisomerase II** Page 197  
*Giselle Sholler; Erika Currier; Andre Bachmann*  
 United States
- POT75 The genetic and clinical implications of MYCN gain in neuroblastoma** Page 197  
*Ryota Souzaki; Tatsuro Tajiri; Risa Teshiba; Yoshiaki Kinoshita; Sakura Tanaka; Tomoaki Taguchi*  
 Japan
- POT76 A new syngeneic MYCN-overexpressing neuroblastoma mouse model and MYCN-DNA vaccine** Page 197  
*Alexander Stermann<sup>1</sup>; Nicole Huebener<sup>2</sup>; Diana Seidel<sup>2</sup>; Anastasia Shibina<sup>2</sup>; Stefan Fest<sup>1</sup>; Holger N. Lode<sup>1</sup>*  
<sup>1</sup>Germany; <sup>2</sup>United States

- POT77 Deregulation of rho/ras rnd neuronal differentiation pathways is associated with fatal outcome in high-risk disseminated neuroblastoma** Page 197  
*Sara Stigliani*<sup>1</sup>; *Simona Coco*<sup>1</sup>; *Stefano Moretti*<sup>2</sup>; *André Oberthuer*<sup>3</sup>; *Jessica Theissen*<sup>3</sup>; *Matthias Fischer*<sup>3</sup>; *Francesca Valdora*<sup>1</sup>; *Fabio Gallo*<sup>1</sup>; *Carla De Vecchi*<sup>1</sup>; *Alberto Garaventa*<sup>1</sup>; *Frank Berthold*<sup>3</sup>; *Stefano Bonassi*<sup>1</sup>; *Gian Paolo Tonini*<sup>1</sup>; *Paola Scaruffi*<sup>1</sup>  
<sup>1</sup>Italy; <sup>2</sup>France; <sup>3</sup>Germany
- POT78 Tumor cell detection in autologous stem cell harvests in patients with high risk neuroblastoma** Page 198  
*J Stutterheim*<sup>1</sup>; *F Vree*<sup>1</sup>; *B Hero*<sup>2</sup>; *L Zappeij - Kannegieter*<sup>1</sup>; *C Voermans*<sup>1</sup>; *R Schumacher-Kuckelkorn*<sup>2</sup>; *U Koehl*<sup>2</sup>; *J H Schulte*<sup>2</sup>; *F Niggli*<sup>3</sup>; *M C Fruhwald*<sup>2</sup>; *M M van Noesel*<sup>1</sup>; *C M Niemeyer*<sup>2</sup>; *U Bode*<sup>2</sup>; *F H Schilling*<sup>2</sup>; *C Schultz*<sup>2</sup>; *N Graf*<sup>2</sup>; *M Nathrath*<sup>2</sup>; *I Schmid*<sup>2</sup>; *H N Caron*<sup>1</sup>; *C E van der Schoot*<sup>1</sup>; *G A M Tytgat*<sup>1</sup>  
<sup>1</sup>Netherlands; <sup>2</sup>Germany; <sup>3</sup>Switzerland
- POT79 Functional analysis of the p53 pathway in neuroblastoma cells using the small-molecule MDM2 antagonist nutlin-3** Page 198  
*Tom Van Maerken*<sup>1</sup>; *Ali Rihani*<sup>1</sup>; *Daniel Dreidax*<sup>2</sup>; *Sarah De Clercq*<sup>1</sup>; *Nurten Yigit*<sup>1</sup>; *Jean-Christophe Marine*<sup>1</sup>; *Frank Westermann*<sup>2</sup>; *Anne De Paepe*<sup>1</sup>; *Frank Speleman*<sup>1</sup>; *Jo Vandesompele*<sup>1</sup>  
<sup>1</sup>Belgium; <sup>2</sup>Germany
- POT80 Detection of microRNAs in bone marrow from children with high-risk neuroblastoma predicts survival; a UK CCLG study.** Page 198  
*Virginie Viprey*<sup>1</sup>; *Maria Corrias*<sup>2</sup>; *Walter Gregory*<sup>3</sup>; *Penelope Brock*<sup>1</sup>; *Susan Burchill*<sup>1</sup>  
<sup>1</sup>United Kingdom; <sup>2</sup>Italy; <sup>3</sup>United Kingdom
- POT81 SKP2-mediated neuroblastoma dedifferentiation is triggered by MYCN through CDK4 induction** Page 199  
*Frank Westermann*<sup>1</sup>; *Daniel Muth*<sup>1</sup>; *Daniel Dreidax*<sup>1</sup>; *Christina Pöhler*<sup>1</sup>; *Sina Gogolin*<sup>1</sup>; *Matthias Fischer*<sup>1</sup>; *Kai Henrich*<sup>1</sup>; *Volker Ehemann*<sup>1</sup>; *Paul Gillespie*<sup>2</sup>; *Manfred Schwab*<sup>1</sup>  
<sup>1</sup>Germany; <sup>2</sup>United States
- POT82 DHA is converted to hydroperoxides and POTentiates the cytotoxic effect of chemotherapeutics in neuroblastoma** Page 199  
*Malin Wickström*<sup>1</sup>; *Helena Gleissman*<sup>1</sup>; *Rong Yang*<sup>2</sup>; *Kimberly Martinod*<sup>2</sup>; *Charles N. Serhan*<sup>2</sup>; *John Inge Johnsen*<sup>1</sup>; *Per Kogner*<sup>1</sup>  
<sup>1</sup>Sweden; <sup>2</sup>United States
- POT83 Exploiting cell cycle aberrations in neuroblastoma by targeting checkpoint kinase chk1 using AZD7762 in neuroblastoma with p14<sup>ARF</sup>/MDM2/p53 defects** Page 199  
*Hong Xu*; *Xiao Wei*; *Irene Cheung*; *Nai-Kong Cheung*  
United States
- POT84 Preoperative analysis of 11q loss of heterozygosity using circulating tumor-released DNA in serum: A novel diagnostic tool for therapy stratification of neuroblastoma** Page 199  
*Shigeki Yagyu*; *Tomoko Iehara*; *Takahiro Gotoh*; *Mitsuru Miyachi*; *Yoshiki Katsumi*; *Ken Kikuchi*; *Kunihiko Tsuchiya*; *Shinya Osone*; *Hiroshi Kuroda*; *Hajime Hosoi*  
Japan
- POT85 Neuroblastoma tumor initiating cells express CD22 making them susceptible to HA22 anti-CD22 immunotoxin induced cell death** Page 200  
*Shuang Yan*<sup>1</sup>; *Zhijie Li*<sup>1</sup>; *Amy McKee*<sup>1</sup>; *Maryalice Stetler-Stevenson*<sup>1</sup>; *Loen Hansford*<sup>2</sup>; *David Kaplan*<sup>2</sup>; *Alan Wayne*<sup>1</sup>; *Ira Pastan*<sup>1</sup>; *Carol J Thiele*<sup>1</sup>  
<sup>1</sup>United States; <sup>2</sup>Canada
- POT86 Genotype-guided neuroblastoma therapy, CP751,871 or Rapamycin** Page 200  
*Libo Zhang*; *Herman Yeger*; *Reza Mokhtari*; *Paula Marrano*; *Paul Thorner*; *David Kaplan*; *Sylvain Baruchel*  
Canada

## Posters – Clinical

- POC1 Neuroblastoma in children-experience in Croatia** Page 201  
*Mirna Anicic; Ljubica Rajic; Ranka Femenic; Ernest Bilic; Josip Konja*  
Croatia
- POC2 Phase I study of single agent perifosine for recurrent pediatric solid tumors** Page 201  
*Oren Becher; Yasmin Khakoo; Shakeel Modak; David Lyden; Stephen Gilheeneey; Jill Kolesar; Tanya Trippett; Eric Holland; Brian Kushner; Nai-Kong Cheung; Kim Kramer; Sofia Haque; Camelia Sima; Ira Dunkel*  
United States
- POC3 Does the amount of bone marrow disease determinate the outcome of patients with stage 4 neuroblastoma?** Page 201  
*Frank Berthold; Roswitha Schumacher-Kuckelkorn; Barbara Hero; Thorsten Simon*  
Germany
- POC4 Outcome of metastatic neuroblastoma treated with multi-modality approach including murine antiganglioside-2 monoclonal antibody (3F8)** Page 201  
*Godfrey Chi-Fung Chan; Matthew Ming-Kong Shing; Rever Chak-Ho Li; Chun-Wing Luk; Siu-Cheung Ling; Chi-Kong Li; Shau-Yin Ha; Paul Kong-Hang Tam*  
China
- POC5 Plasma fractionated total metanephrines for biochemical diagnosis of neuroblastoma** Page 202  
*Laura Crosazzo Franscini; Eric Grouzmann; Mohamed Faouzi; Maja Beck Popovic*  
Switzerland
- POC6 Apoptotic and adjuvant effects of triterpene-containing *Viscum album* L. extracts in neuroblastoma** Page 202  
*Catharina Delebinski; Kristin Kemnitz-Hassanin; Ulrike Schmidt; Sebastian Jäger; Holger Lode; Georg Seifert*  
Germany
- POC7 Phase I study of vincristine, irinotecan, and <sup>131</sup>I-MIBG for patients with relapsed or refractory neuroblastoma: A new approaches to neuroblastoma therapy consortium study** Page 202  
*Steven DuBois<sup>1</sup>; Louis Chesler<sup>2</sup>; Susan Groshen<sup>1</sup>; Randall Hawkins<sup>1</sup>; Hollie Jackson<sup>1</sup>; Heike Daldrup-Link<sup>1</sup>; Greg Yanik<sup>1</sup>; Clinton Stewart<sup>1</sup>; Yael Mosse<sup>1</sup>; John Maris<sup>1</sup>; Judith Villablanca<sup>1</sup>; Katherine Matthay<sup>1</sup>*  
<sup>1</sup>United States; <sup>2</sup>United Kingdom
- POC8 Five-day courses of irinotecan in chinese patients with refractory neuroblastoma** Page 202  
*Qiushi Fan; Jinhua Zhang; Hongyu Zhao; Huawei Zou*  
China
- POC9 Gefitinib (GFB) and Irinotecan (IRN) for children with high-risk (HR) neuroblastoma (NB)** Page 203  
*Wayne Furman; Lisa McGregor; Clinton Stewart; Mihaela Onciu; Sandy Kovach; Andrew Davidoff; Victor Santana*  
United States
- POC10 Does tumor histology after induction therapy predict outcome in patients with high-risk neuroblastoma?** Page 203  
*Rani E. George; Antonio Perez-Atayde; Xiaopan Yao; Wendy B. London; Robert C. Shamberger; Lisa Diller*  
United States
- POC11 Aromatic hydrocarbon receptor down-regulates MYCN expression and promotes neuronal differentiation of neuroblastoma** Page 203  
*Wen-Ming Hsu; Pei-Yi Wu; Hsueh-Fen Juan; Hsinyu Lee*  
Taiwan
- POC12 Results of treatment strategy of stage 4 infantile neuroblastoma based on born metastasis and Mycn amplification** Page 203  
*Tomoko Iehara; Minoru Hamazaki; Takeo Tanaka; Hajime Hosoi; Tatsuro Tajiri; Michio Kaneko; Tohru Sugimoto; Tadashi Sawada*  
Japan

- POC13 Is there an Ultra-High-Risk neuroblastoma group? Report from the Children's Oncology Group (COG) Clinical and Biological Risk Factors (CBRF) Task Force** Page 204  
*Meredith S. Irwin*<sup>1</sup>; *Arlene Naranjo*<sup>2</sup>; *Edward F. Attiyeh*<sup>2</sup>; *Robert Seeger*<sup>2</sup>; *Shahab Asgharzdeh*<sup>2</sup>; *Richard Sposto*<sup>2</sup>; *Lingyun Ji*<sup>2</sup>; *Gregory Yanik*<sup>2</sup>; *Yael P. Mosse*<sup>2</sup>; *John M. Maris*<sup>2</sup>; *Julie R. Park*<sup>2</sup>; *Wendy London*<sup>2</sup>; *Susan Kreissman*<sup>2</sup>; *Michael D. Hogarty*<sup>2</sup>  
<sup>1</sup>Canada; <sup>2</sup>United States
- POC14 False negative studies of neuroblastoma (NB) metastatic to the central nervous system (CNS)** Page 204  
*Kim Kramer*; *Brian H Kushner*; *Shakeel Modak*; *Yasmin Khakoo*; *Neeta Pandit-Taskar*; *Hilda Stambuk*; *Mark M Souweidane*; *Nai-Kong Cheung*  
 United States
- POC15 Evolution of treatment strategies and risk stratification in management of neuroblastoma (NB) over two decades at tertiary cancer centre in India** Page 204  
*Purna Kurkure*; *Tushar Vora*; *Brijesh Arora*; *Sripad Banavali*; *sajid Qureshi*; *Siddharth Laskar*; *Marryann Muckaden*; *V Seethalaxmi*; *Mukta Ramadwar*; *Sangeeta Desai*; *Seema Medhi*; *MGR Rajan*; *Akash Nahar*; *Gaurav Bahi*; *Seema Gulia*  
 India
- POC16 High-dose cyclophosphamide (Cy)-irinotecan (CPT-11)-vincristine (VCR) (HD-CCV) for primary refractory neuroblastoma (NB)** Page 205  
*Brian Kushner*; *Kim Kramer*; *Shakeel Modak*; *Karima Yataghene*; *Nai-Kong Cheung*  
 United States
- POC17 A proposal for antibody based immunotherapy combined with haploidentical stem cell transplantation for high risk neuroblastoma** Page 205  
*Peter Lang*<sup>1</sup>; *Matthias Pfeiffer*<sup>1</sup>; *Ruth Ladenstein*<sup>2</sup>; *Holger Lode*<sup>1</sup>; *Ingo Müller*<sup>1</sup>; *Teltschik Heiko Manuel*<sup>1</sup>; *Tobias Feuchtinger*<sup>1</sup>; *Philipp Schwarze*<sup>1</sup>; *Rupert Handgretinger*<sup>1</sup>  
<sup>1</sup>Germany; <sup>2</sup>Austria
- POC18 Illness experience and factors that constitute resilience in families with a neuroblastomachild** Page 205  
*Ya-Ling Lee*; *Tzu-Chun Chen*; *Wen-Ming Hsu*  
 Taiwan
- POC19 The impact of a multidisciplinary team approach in the case management of neuroblastoma** Page 205  
*Yen-Lin Liu*; *Wen-Ming Hsu*; *Hsiu-Hao Chang*; *Dong-Tsamn Lin*; *Kai-Hsin Lin*; *Shiann-Tarng Jou*; *Meng-Yao Lu*; *Yung-Li Yang*; *Kai-Yuan Tzen*; *Steven Hsin-Feng Peng*; *Shiu-Feng Huang*; *Ya-Ling Lee*  
 Taiwan
- POC20 Second stem cell transplantation for relapsed high-risk neuroblastoma in Japan** Page 206  
*Kimikazu Matsumoto*; *Koji Kato*; *Committee The Stem Cell Transplantation*  
 Japan
- POC21 Role of minimal access surgery in children affected by neuroblastoma** Page 206  
*Girolamo Mattioli*; *Stefano Avanzini*; *Piero Buffa*; *Alberto Michelazzi*; *Alberto Garaventa*; *Massimo Conte*; *Vincenzo Jasonni*  
 Italy
- POC22 Role of nursing in the implementation of chimeric anti-GD2 antibody with immunotherapy (ANBL0032) into clinical practice** Page 206  
*Denise Mills*; *Anne Marie Maloney*; *Ann Chang*  
 Canada
- POC23 Phase I trial of Lestaurtinib for children with refractory neuroblastoma (NB): A new approaches to neuroblastoma therapy (NANT) study** Page 206  
*Jane E Minturn*; *Audrey E Evans*; *Judith G Villablanca*; *Gregory A Yanik*; *Julie R Park*; *Susan Groshen*; *Edward T Hellriegel*; *Debra Bensen-Kennedy*; *Katherine K Matthay*; *Garrett M Brodeur*; *John M Maris*  
 United States

- POC24 Arsenic trioxide as radiosensitizer for 131I-MIBG therapy: Results of a pilot phase II study** Page 207  
*Shakeel Modak; Neeta Pandit-Taskar; Jorge Carrasquillo; Brian H. Kushner; Kim Kramer; Pat Zanzonico; Peter Smith-Jones; Steven Larson; Nai-Kong V. Cheung*  
 United States
- POC25 Comparison of I-123 and I-131 mIBG scans in predicting survival in patients with stage 4 neuroblastoma** Page 207  
*Arlene Naranjo; Marguerite T. Parisi; Barry L. Shulkin; Wendy B. London; Katherine K. Matthay; Susan G. Kreissman; Gregory A. Yanik*  
 United States
- POC26 Transverse myelopathy in neuroblastoma patients. Retrospective comparison of initial chemotherapy (CT) and neurosurgery (NS)** Page 207  
*Catherina Annika Niemann; Barbara Hero; Boris De Carolis; Frank Berthold; Thorsten Simon*  
 Germany
- POC27 Decision of treatment reduction in selected children aged less than 18 months with a neuroblastoma without MYCN amplification and a numerical genomic profile** Page 207  
*Charline Normand; Gudrun Schleiermacher; Gaele Pierron; Agnès Ribeiro; Isabelle Janoueix-Lerosey; Pascale Philippe-Chomette; Thierry Van den Abbeele; Sabine Sarnacki; Y. Manach; Olivier Delattre; Jean Michon*  
 France
- POC28 Retinoids (RA) relieve EZH2-mediated epigenetic suppression of neuroblastoma (NB) differentiation** Page 208  
*Doo-Yi Oh<sup>1</sup>; Chan-Wook Woo<sup>2</sup>; Chunxi Wang<sup>1</sup>; Javed Khan<sup>1</sup>; Carol J Thiele<sup>1</sup>*  
<sup>1</sup>United States; <sup>2</sup>Republic of Korea
- POC29 Development of an automated quantitative method for scoring Metaiodobenzylguanidine (mIBG)scans in patients with neuroblastoma** Page 208  
*Navin Pinto<sup>1</sup>; Hiroyuki Abe<sup>1</sup>; Daniel Appelbaum<sup>1</sup>; Takeshi Hara<sup>2</sup>; Yonglin Pu<sup>1</sup>; Junji Shiraishi<sup>1</sup>; Kunio Doi<sup>1</sup>; Susan L. Cohn<sup>1</sup>; Samuel L. Volchenbom<sup>1</sup>*  
<sup>1</sup>United States; <sup>2</sup>Japan
- POC30 Is retroperitoneal lymphadenectomy for high risk abdominal neuroblastoma relevant** Page 208  
*Sajid Qureshi; Purna Kurkure; Seethalakshmi Vishwanathan; Mukta Ramadwar; Sidharth Laskar*  
 India
- POC31 Concurrent ipsilateral nephrectomy versus kidney-sparing surgery in high-risk, intra-abdominal neuroblastoma** Page 209  
*Amanda Roberts; Ahmed Nasr; Meredith Irwin; J. Ted Gerstle*  
 Canada
- POC32 Pilot study of high-dose chemotherapy using a novel preparative regimen with Busulfan, Melphalan, and Topotecan (TBM) followed by autologous hematopoietic stem cell transplant in high-risk neuroblastoma and other advanced stage and recurrent tumors** Page 209  
*Joseph Rosenthal; Anna Pawlowska; Ellen Bolotin; Hossameldin Naeem; Andrew Daxis; Dajun Qian; Clarke Anderson*  
 United States
- POC33 Immunocytological GD2 negativity in treated and untreated neuroblastoma patients with bone marrow metastases** Page 209  
*Roswitha Schumacher-Kuckelkorn; Barbara Hero; Anke Gradehandt; Thorsten Simon; Frank Berthold*  
 Germany
- POC34 Hematopoietic stem cell transplantation for high risk neuroblastoma in children** Page 209  
*Larisa Shelikhova*  
 Russian Federation
- POC35 Follow-up study of survivors of childhood neuroblastoma - Report from a single institute in Japan** Page 210  
*Hiroyuki Shichino; Motoaki Chin; Hirotsugu Okuma; Eri Nishikawa; Maiko Hirai; Maiko Kato; Hiroshi Yagasaki; Tatsuhiko Urakami; Naokata Sumitomo; Yasuji Inamo; Hideo Mugishima*  
 Japan

- POC36 Retrospective analysis of treatment results of high risk neuroblastoma** Page 210  
*Egor Shorikov; Olga Lemesheva; Tatiana Popova; Igor Vyatkin; Grigory Tsaur; Alexander Popov; Leonid Saveliev; Larisa Fechina*  
*Russian Federation*
- POC37 Comparison of anti-GD2-antibody ch14.18 and 13-cis-retinoic acid as consolidation therapy for high-risk neuroblastoma. Results of the German NB97 trial** Page 210  
*Thorsten Simon; Barbara Hero; Rupert Handgretinger; Martin Schrappe; Thomas Klingebiel; Michael C Fruehwald; Guenther Henze; Frank Berthold*  
*Germany*
- POC38 Metachronous neuroblastoma in an infant with constitutional unbalanced translocation t(2;16)(p23;p13.3) involving ALK** Page 210  
*Shui Yen Soh; Dimitri Stavropoulos; Sarah Bowdin; Paul Thorner; Sylvain Baruchel; David Malkin; M. Stephen Meyn; Meredith Irwin*  
*Canada*
- POC39 Neuroblastomas with non-avid I<sup>123</sup>-MIBG scan and negative urinary catecholamine secretion: A single institute's experience** Page 211  
*Shui Yen Soh; Sylvain Baruchel; Meredith Irwin*  
*Canada*
- POC40 Efficacy of tandem high-dose chemotherapy and autologous stem cell rescue in patients with high-risk neuroblastoma: a preliminary report of NB 2004 study at Samsung Medical Center** Page 211  
*Ki Woong Sung; Heewon Cheuh; Soo Hyun Lee; Keon Hee Yoo; Hong Hoe Koo; Juyoun Kim; Eun Joo Cho; Kun Soo Lee*  
*Republic of Korea*
- POC41 Measurement of tyrosine hydroxylase transcripts in bone marrow using biopsied tissue instead of aspirate for neuroblastoma** Page 211  
*Ki Woong Sung; Seung-Tae Lee; Yeon Lim Suh; Young-Hyeh Ko; Chang-Seok Ki; Hee-Jin Kim; Jong-Won Kim; Sun-Hee Kim; Heewon Chueh; Soo Hyun Lee; Keon Hee Yoo; Hong Hoe Koo*  
*Republic of Korea*
- POC42 Reduced-intensity allogeneic stem cell transplantation in children with neuroblastoma who have failed a prior tandem autologous stem cell transplantation** Page 211  
*Ki Woong Sung; Heewon Cheuh; Soo Hyun Lee; Keon Hee Yoo; Hong Hoe Koo; Juyoun Kim*  
*Republic of Korea*
- POC43 Neuroblastoma detected after ending of mass screening at 6 months of age in Japan** Page 212  
*Tatsuro Tajiri; Ryota Souzaki; Yoshiaki Kinoshita; Sakura Tanaka; Yuhki Koga; Aiko Suminoe; Toshiro Hara; Tomoaki Taguchi*  
*Japan*
- POC44 Whole-body diffusion-weighted MR imaging is useful to detect bone/bone marrow metastasis of neuroblastoma and monitor response to therapy** Page 212  
*Yoshiyuki Takahashi; Nobuhiro Nishio; Hideki Muramatsu; Akira Shimada; Asahito Hama; Masafumi Ito; Kenichiro Kaneko; Hisami Ando; Hisroshi Fukatsu; Seiji Kojima*  
*Japan*
- POC45 Identification of a therapy-sensitive subtype and stratification of progressive risk in advanced neuroblastomas** Page 212  
*Takeo Tanaka; Yohko Kyo; Kunihiko Hayashi; Tomoko Iehara; Hajime Hosoi; Tohru Sugimoto; Minoru Hamasaki; Michio Kaneko; Tadashi Sawada*  
*Japan*
- POC46 <sup>18</sup>F-FDOPA PET scan is still useful in the presence of <sup>123</sup>I-MIBG and <sup>18</sup>F-FDG for neuroblastoma imaging** Page 212  
*Kai-Yuan Tzen; Meng-Yao Lu; Hsiu-Hao Chang; Wen-Ming Hsu; Tsai-Yueh Luo; Lie-Hang Shen*  
*Taiwan*
- POC47 Molecular imaging with <sup>18</sup>F-FDOPA PET in the early detection of new metastatic neuroblastoma in bone marrow** Page 213  
*Kai-Yuan Tzen; Meng-Yao Lu; Hsiu-Hao Chang; Wen-Ming Hsu*  
*Taiwan*

- POC48 Efficacy of Treosulfan as a single agent in newly diagnosed neuroblastoma stage IV patients** Page 213  
*Boyarshinov Vasiliy; Dolgoplov Igor; Pimenov Roman; Mentkevich George*  
*Russian Federation*
- POC49 Irinotecan/Temodal therapy as salvage treatment for children with neuroblastoma - single centre experience** Page 213  
*Aleksandra Wieczorek; Walentyna Balwierz*  
*Poland*
- POC50 Minimal disease detection in non-metastatic neuroblastoma patients** Page 213  
*Yania Yañez; Elena Grau; Silvestre Oltra; Adela Cañete; Francisco Martinez; Carmen Orellana; Rosa Noguera; Samuel Navarro; Victoria Castel*  
*Spain*
- POC51 Clinical report on the treatment of children in the late stage of neuroblastoma using chemotherapy combined with Zhongluo 3** Page 214  
*Jinhua Zhang; Suning Chen; Fei Yu*  
*China*
- Posters – Late Breakers**
- POLB1 Effect of retinoic acid and chemotherapeutic agents on ultrastructural localization of Myc-N in neuroblastoma** Page 214  
*Safiye Aktas; Zekiye Altun; Candan Ozogul; Nur Olgun; Dilek Gunes*  
*Turkey*
- POLB2 Betulinic acid affects metastasis related genes in neuroblastoma cells** Page 214  
*Zekiye Altun; Safiye Aktas; Dilek Gunes; Nur Olgun*  
*Turkey*
- POLB3 Human neuroblastoma microenvironment supports T-cell activation in tumor associated lymphocytes** Page 215  
*Lena-Maria Carlson; Anna DeGeer; Baldur Sveinbjörnsson; Abiel Orrego; Tommy Martinsson; Per Kogner; Jelena Levitskaya*  
*Sweden*
- POLB4 Expectant management of congenital adrenal neuroblastoma** Page 215  
*Dennis A Cozzi; Amalia Schiavetti; Ermelinda Mele; Silvia Ceccanti; Simone Frediani; Anna Clerico; Carlo Dominici*  
*Italy*
- POLB5 Allicin increases metastasis related genes in neuroblastoma** Page 215  
*Dilek Gunes; Safiye Aktas; Zekiye Altun; Nur Olgun*  
*Turkey*
- POLB6 Diagnostics and treatment of children with localized and locally advanced thoracoabdominal neuroblastoma** Page 215  
*Anatoly Kazantsev; Andrey Ryabov; Polad Kerimov; Andrey Volobuev; Mikhail Rubansky*  
*Russian Federation*
- POLB7 Modeling the p53-Mdm2 core module in neuroblastoma** Page 216  
*Florian Lamprecht; Daniel Dreidax; Sina Gogolin; Christina Pöhler; Manfred Schwab; Frank Westermann; Thomas Höfer*  
*Germany*
- POLB8 Biological characteristics of neuroblastoma in children of Belarus** Page 216  
*Inna Proleskovskaya; Alena Valochnik; Natallia Savva*  
*Belarus*
- POLB9 Treatment results for neuroblastoma in children of Belarus** Page 216  
*Inna Proleskovskaya; Tatyana Savich; Dmitriy Kochubinsky; Natallia Savva; Olga Aleinikova*  
*Belarus*

**POLB10 Autochthonous TNF alpha as an inducer of immune resistance and survival of neuroblastoma** Page 216

*Elian Rakhmanaliev<sup>1</sup>; Jinxia Ma<sup>1</sup>; Victor Levitsky<sup>1</sup>; Murray Norris<sup>2</sup>; Jelena Levitskaya<sup>1</sup>*  
*<sup>1</sup>United States; <sup>2</sup>Australia*

**POLB11 Identifying lesions in translational control of gene expression in neuroblastoma by mRNA polysomal profiling and information-intensive computational integration** Page 217

*Angela Re; Erik Dassi; Viktoryia Sidarovich; Toma Tebaldi; Paola Scaruffi; Gian Paolo Tonini; Alessandro Quattrone*  
*Italy*

**POLB12 An integrative bioinformatics approach in neuroblastoma identifies converging alterations in protein networks related to mitotic spindle assembly and splicing** Page 217

*Ooi Wen Fong; Angela Re; Natalia Arseni; Valentina Canella; Giulia Guarguaglini; Patrizia Lavia; Paola Scaruffi; Gian Paolo Tonini; Alessandro Quattrone*  
*Italy*

**POLB13 Induction of human embryonic stem cells into sympathoadrenal cells** Page 217

*Michael D Hadjidaniel; Shahab Asgharzadeh*  
*United States*